Status:
TERMINATED
Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Lead Sponsor:
King Chulalongkorn Memorial Hospital
Conditions:
Malignant Biliary Strictures
Eligibility:
All Genders
20+ years
Brief Summary
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures Objectives 1. To assess the sensitivity, specificity and accuracy of CholangioFlex in ...
Detailed Description
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures Objectives 1. To assess the sensitivity, specificity and accuracy of CholangioFlex in ...
Eligibility Criteria
Inclusion
- Age \> 20 year-old
- All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
- All patients have to sign the consent form
Exclusion
- Cannot follow up for 1 year
- Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants
- Pregnancy
- History of fluorescein allergy
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01501474
Start Date
January 1 2012
End Date
July 1 2014
Last Update
February 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rapat Pittayanon
Bangkok, Thailand, 10330